Literature DB >> 7726533

Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid.

Y Wang1, C Luscombe, S Bowden, T Shaw, S Locarnini.   

Abstract

The aim of this study was to examine the effects of ganciclovir and nalidixic acid either alone or in combination on duck hepatitis B virus DNA replication in vivo with particular reference to production of viral supercoiled DNA and RNA. The most effective antiviral response was observed in the livers of ducks treated by the combination therapy for 28 days, which resulted in a substantial decrease in the amounts of viral supercoiled DNA, relaxed circular and single-stranded DNA, and also viral RNA. This combination treatment was not hepatotoxic over the study period.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7726533      PMCID： PMC162580          DOI： 10.1128/AAC.39.2.556

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Approaches to the treatment of hepatitis B virus and delta-related liver disease.

Authors:  H C Thomas; A M Lever; L J Scully; M Pignatelli
Journal:  Semin Liver Dis       Date:  1986-02       Impact factor: 6.115

2.  Appearance of viral RNA transcripts in the early stage of duck hepatitis B virus infection.

Authors:  M Tagawa; M Omata; K Okuda
Journal:  Virology       Date:  1986-07-30       Impact factor: 3.616

3.  In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus.

Authors:  B Lee; W X Luo; S Suzuki; M J Robins; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

4.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

5.  Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase.

Authors:  C Kassianides; J H Hoofnagle; R H Miller; E Doo; H Ford; S Broder; H Mitsuya
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

6.  Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.

Authors:  C Luscombe; J Pedersen; S Bowden; S Locarnini
Journal:  Liver       Date:  1994-08

7.  Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Authors:  G J Alexander; J Brahm; E A Fagan; H M Smith; H M Daniels; A L Eddleston; R Williams
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

8.  Virus-liver cell interactions in duck hepatitis B virus infection. A study of virus dissemination within the liver.

Authors:  A R Jilbert; J S Freiman; C J Burrell; M Holmes; E J Gowans; R Rowland; P Hall; Y E Cossart
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

9.  Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection.

Authors:  K Hirota; A H Sherker; M Omata; O Yokosuka; K Okuda
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

10.  Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks.

Authors:  A H Sherker; K Hirota; M Omata; K Okuda
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682
View more
  7 in total

1.  Duck hepatitis B virus replication in primary bile duct epithelial cells.

Authors:  J Y Lee; J G Culvenor; P Angus; R Smallwood; A Nicoll; S Locarnini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

Authors:  G Civitico; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 3.  Combination chemotherapy for hepatitis B virus: the path forward?

Authors:  T Shaw; S Locarnini
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

Review 4.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

5.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; Y Y Wang; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.